Abstract:Background Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for prediction of the immune response limit the clinical application of anti-PD-1 immunotherapy. Our recent work showed that a combination of low-dose decitabine and PD-1-ab significantly improved the complete response (CR) rate of cHL patients from 32 to 71%, which indicates that there is a significant correlation between epigenetic regulation and the clinical response to immunotherapy. Methods We recruited two groups of Hodgkin lymphoma patients who were treated with anti-PD-1 and DAC+anti-PD-1. CD8+ T cells were isolated from the patients' peripheral blood, DNA methylation was analyzed by EPIC, the expression profile was analyzed by RNA-seq, and multigroup analysis was performed with IPA and GSEA functional annotations. We explored the effect of DAC on the function of CD8+ T cells in the blood, spleen, tumor and lymph nodes using a mouse model. Furthermore, we explored the function of Tils in the tumor microenvironment. Then, we constructed Runx3-knockout mice to confirm the T-cell-specific function of Runx3 in CD8+ T cells and analyzed various subtypes of T cells and cytokines using mass cytometry (CyTOF). Results Multiomics analysis identified that DNA methylation reprogramming of Runx3 was a crucial mediator of CD8+ T-cell function. Multiomics data showed that reversal of methylation of the Runx3 promoter promoted the infiltration of CD8+ TILs and mitigated the exhaustion of CD8+ T cells. Furthermore, experiments on tissue-specific Runx3-knockout mice showed that Runx3 deficiency reduced CD8+ T infiltration and the differentiation of effector T and memory T cells. Furthermore, Runx3 deficiency significantly decreased CCR3 and CCR5 levels. Immunotherapy experiments in Runx3 conditional knockout mice showed that DAC could not reverse the resistance of anti-PD-1 in the absence of Runx3. Moreover, both our clinical data and data from TISIDB showed that Runx3 could be a potential biomarker for immunotherapy to predict the clinical response rate. Conclusion We demonstrate that the DNA methylation of Runx3 plays a critical role in CD8+ T-cell infiltration and differentiation during decitabine-primed PD-1-ab immunotherapy, which provides a supporting mechanism for the essential role of epiregulation in immunotherapy.

Decitabine priming increases anti–PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models

Sequential Combination of Decitabine and Idarubicin Synergistically Enhances Anti-Leukemia Effect Followed by Demethylating Wnt Pathway Inhibitor Promoters and Downregulating Wnt Pathway Nuclear Target

Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses.

Priming with LSD1 Inhibitors Promotes the Persistence and Antitumor Effect of Adoptively Transferred T Cells

Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming

Synergistic Depression of Wnt Pathway by Sequential Combination of Decitabine and Idarubicin in Human Myeloid Leukemic Cell Lines

Low-Dose Decitabine Augments the Activation and Anti-Tumor Immune Response of IFN-γ+ CD4+ T Cells Through Enhancing IκBα Degradation and NF-κB Activation

IFN-γ Down-Regulates the PD-1 Expression and Assist Nivolumab in PD-1-blockade Effect on CD8+ T-lymphocytes in Pancreatic Cancer

Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

Epigenetic Agents Plus Anti-Pd-1 Reshapes Tumor Microenvironment and Restores Antitumor Efficacy in Hodgkin Lymphoma

Epigenetic Reprogramming of Runx3 Reinforces CD8 + T-cell Function and Improves the Clinical Response to Immunotherapy.

Efficacy of Decitabine plus Anti-PD-1 Camrelizumab in Patients with Hodgkin Lymphoma Who Progressed or Relapsed after PD-1 Blockade Monotherapy

Decitabine Inhibits T Cell Proliferation Via a Novel TET2-dependent Mechanism and Exerts Potent Protective Effect in Mouse Auto- and Allo-Immunity Models.

Cell-intrinsic PD-L1 Ablation Sustains Effector CD8+ T Cell Responses and Promotes Antitumor T Cell Therapy

Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling

CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer

Reinvigorated exhausted T cells exhibit distinct features within 24 hours after PD-1 therapy

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

Low-dose DNA-demethylating Agent Enhances the Chemosensitivity of Cancer Cells by Targeting Cancer Stem Cells Via the Upregulation of Microrna-497

Tetrahydrouridine-decitabine for Non-Cytotoxic Epigenetic Therapy of NSCLC to Enhance Immunotherapeutic Effect of Anti-Pd1 in Vivo.